Company / Capital Expenditures
Cullinan Therapeutics, Inc. Capital Expenditures History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
-
FY2024
5-year range
$0 / $1.1M
FY2020-FY2024
Trend
-100.0%
vs FY2023
Sector context
#190 of 194
Health Care
What the data says
Declined from $1M to $0 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 194
▼
Key checks
Key Insights
- In FY2024, capital expenditures decreased 100.0% year-over-year.
- Peak capital expenditures was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.33 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $0 | -100.0% |
| FY2023 | $208.0K | -81.6% |
| FY2022 | $1.1M | +11230.0% |
| FY2021 | $10.0K | +0.0% |
| FY2020 | $10.0K | - |
As of FY2024 · SEC 10-K · Updated Jul 2, 2026